Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) saw recent insider activity as director Howard G. Welgus liquidated a portion of his holdings in the company. On May 1, 2026, Mr. Welgus sold a total of 7,144 shares of common stock. The proceeds from these transactions amounted to approximately $164,219, with the shares being sold at various price points ranging from $22.79 to $23.25 per share.
Execution via Automated Trading Plan
The transaction was carried out in accordance with a pre-arranged 10b5-1 trading plan. Mr. Welgus established this plan on March 11, 2025, and the scheduled expiration for the current plan is May 29, 2026. Such plans are designed to facilitate scheduled trades by insiders. Despite the sale, Mr. Welgus retains a substantial direct interest in Arcutis Biotherapeutics, holding 32,600 shares of common stock following this transaction.
Clinical and Regulatory Pipeline Developments
The insider activity coincides with several key strategic milestones for the company's product pipeline. Arcutis has recently submitted a supplemental New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). This application seeks to expand the indicated use of ZORYVE cream, aiming to treat mild to moderate atopic dermatitis in infants as young as three months old. The submission is supported by data gathered from two distinct clinical trials.
The clinical utility of ZORYVE cream has also received recognition from professional medical bodies. The American Academy of Dermatology has integrated Zoryve cream into its clinical practice guidelines for the treatment of pediatric atopic dermatitis. The academy cited a high level of certainty regarding the efficacy, safety, and tolerability of the cream in its recommendation.
Furthermore, Arcutis has shared results from its INTEGUMENT-INFANT Phase 2 trial, which indicated significant improvements in infants suffering from atopic dermatitis when treated with ZORYVE. Supporting documentation for FDA approval also includes a Phase 3 open-label extension study published in Pediatric Dermatology, which examined the long-term application of the cream in children between the ages of 2 and 5 years.
In addition to its current cream, Arcutis is expanding its research into biologics. The company has announced the enrollment of the first participant in a Phase 1a/1b study for ARQ-234. This investigational biologic is being studied for the treatment of moderate to severe atopic dermatitis, with this specific trial focusing on assessing safety and tolerability levels in adult patients.
Market Context and Financial Health
From a market perspective, Arcutis stock has experienced a strong upward trend, delivering a 63.55% return over the last year. While the recent sale by Mr. Welgus occurs near the current trading price of $23.42, certain financial analyses indicate that the stock remains undervalued based on fair value metrics. Additionally, the company's financial health has been characterized as "GREAT" according to specialized research scoring.